Table 4.
Variable (%)a,b | Median (IQR) | p valuec |
---|---|---|
CD4+FoxP3+ | 0.29 (−2.50, 1.59) | 0.97 |
CD4+IL-10+ | 0.37 (−2.08, 1.78) | 0.87 |
CD4+IL-10+FoxP3+ | −0.04 (−0.34, 0.18) | 0.40 |
CD4+TGF-β+ | −0.99 (−3.83, 0.87) | 0.02 |
CD4+TGF-β+FoxP3+ | −0.11 (−0.56, 0.27) | 0.14 |
CD8+FoxP3+ | 0.51 (−2.59, 3.65) | 0.53 |
CD8+IL-10+ | 0.55 (−2.23, 2.26) | 0.40 |
CD8+IL-10+FoxP3+ | 0.12 (−0.40, 0.82) | 0.48 |
CD8+TGF-β+ | −0.79 (−3.59, 1.21) | 0.18 |
CD8+TGF-β+FoxP3+ | −0.15 (−0.55, 0.85) | 0.98 |
CD19+FoxP3+ | 0.47 (−1.53, 2.54) | 0.46 |
CD19+IL-10+ | −0.71 (−4.13, 2.70) | 0.47 |
CD19+IL-10+FoxP3+ | −0.01 (−0.16, 0.33) | 0.49 |
CD19+TGF-β+ | 0.08 (−3.66, 1.11) | 0.51 |
CD19+TGF-β+FoxP3+ | 0.01 (−0.35, 0.24) | 0.73 |
N = 45
Subsets, measured by flow cytometry, are expressed as a percentage of the parent CD4+, CD8+, or CD19+ population.
Wilcoxon matched pairs signed-rank test.
Bold represents the values that were significant at a 0.05 level.